Answers are grounded in this paper and cite their sources.
Two novel types of exploratory clinical study concepts, the phase 0 trial and microdosing, are being used increasingly in the anticancer drug development process. Th ese trials allow investigators to test a very small drug dose to see if it behaves as expected in humans without going through the more stringent requirements of a traditional phase I clinical trial. Incorporation of these concepts can potentially quickly weed out investigational drugs that are metabolically and/or biologically ineff ective and provide valuable insight into whether to move forward with additional clinical trials. Th e small doses used in phase 0/ microdosing studies require the availability of ultrasensitive analytical tools to detect drug levels in biological specimens. Currently, accelerator mass spectrometry (AMS) is the most widely used method in the context of microdosing to obtain early information on pharmacokinetics, whereas imaging with positron emission tomography (PET) is being actively explored to provide real-time pharmacodynamic information. It is anticipated that, in the near future, microdosing will become an integrated approach to human studies aimed at understanding basic pharmacologic properties of both investigational and approved oncology drugs, especially for those that require continuous dosing. Background and Materials Th e publication of the US Food and Drug Administration’s “Critical Path” document highlights the importance of translational research and the development of new concepts and tools that may help provide more confi dence in the selection of drug candidates early in clinical development (1). One type of exploratory study, the so-called phase 0 trial, allows dosing to pharmacologic response and limited multiple dosing of investigational agents in patients with cancer (2). Another type of exploratory investigation supported by both European and US regulatory agencies is a microdose study, which involves the administration of a compound in humans given at a dose that is less than 1/100 of the (predicted) therapeutic dose, up to a maximum of 100 micrograms. In such studies, early human data can be obtained on basic pharmacokinetic parameters, such as clearance, volume of distribution and half-life. Microdosing is dependent on the availability of ultrasensitive analytical methods that are capable of measuring drug and metabolite concentrations in the low pictogram to femtogram range. Accelerator mass spectrometry (AMS) and positron emission tomography (PET) are the most widely used methods used to support microdosing studies in humans (3). Both of these techniques rely on the analysis of radioisotopes incorporated into the drugs under study, usually carbon-14 for AMS and carbon-11 for PET. AMS is used primarily for determining pharmacokinetic data by collection of serial blood samples over a Author Affi liations: St. Jude Children’s Research Hospital, Memphis, Tennessee ©2008 American Association for Cancer Research Pharmacokinetic Applications in Drug Development 702 AACR Annual Meeting 2008 • April 12–16, 2008 period of time after initial drug administration, followed by sample processing and drug content determination. Because of the short decay-half life of carbon-11 isotopes, PET typically provides primarily pharmacodynamic data through real-time imaging, and only some limited kinetic data (up to about 2 half-lives). Clinical and Translational Leads Incorporation of the phase 0 and microdosing strategies has the potential to reduce attrition in the clinical development of anticancer drugs, although their value as major retooling approaches to the drug development process has been questioned (4). Phase 0 trials are currently being perceived and explored mainly as a platform to establish the feasibility of assays for target modulation in human samples, as well as to evaluate biomarkers for eff ects of molecularly targeted agents (5). Th e principal applications of the microdosing concept have been to assist in the selection process when multiple new chemical entities are available, to obtain preliminary pharmacokinetic information for investigational new drugs early in the development process, and to confi rm in vitro or in silico metabolic pathways in humans (2). Beyond being a potential tool in the selection of drug candidates, microdosing has been widely used to obtain phenotypic information on enzyme or transporter activity, for example with the administration of small doses of erythromycin or midazolam in order to assess an individual’s cytochrome P450 3A4 (CYP3A4) activity (6). Th e current availability of advanced analytical equipment that permits detection of low concentrations of a drug in human matrices (such as AMS) also enables microdosing to be used in the application of previously unfeasible study designs in oncology and unanswerable questions to be investigated experimentally. Unfortunately, the current database for microdosing studies is still extremely limited, and includes less than half a dozen anticancer drugs such as tipifarnib (7) and imatinib (8). Th is lack of available data is due in part to the length of time required to get new approaches adopted, the lack of appropriate validation programs, and a failure to recognize the potential benefi ts of this approach (2). Nonetheless, adoption of this technique is accelerating as the regulatory climate in both the US and Europe has changed, permitting microdose studies to be conducted with a minimal toxicology package. Challenges and Future Directions A signifi cant limitation of the use of microdosing is the potential for poor predictability of pharmacokinetic information obtained with a microdose versus a therapeutic dose due to the occurrence of nonlinear absorption or disposition patterns of the drug in question. However, although no exhaustive data are currently available, it has been suggested recently that for the majority of prescription drugs an acceptable degree of concordance can be anticipated (9). One currently unexplored opportunity is the utility of microdosing to evaluate the contribution of germline variants in genes with a confi rmed or suspected role in the pharmacokinetics of oncology drugs. Identifi cation of genetic and environmental factors associated with interindividual variability in the absorption and disposition of such drugs is vital to predicting or eventually adapting appropriate, individualized doses. However, traditionally, pharmacogenetic studies in oncology have been mostly retrospective, uncontrolled, expensive, contradictory, and underpowered due to the limited number of patients evaluated that Pharmacokinetic Studies in Microdosing and Phase 0 Trials AACR Education Book • http://educationbook.aacrjournals.org 703 carry the variant genotypes of interest (10). Th is is an unsustainable situation in need of an appropriate and cost-eff ective solution. Th e low (radioactive) systemic exposure to anticancer drugs associated with a single microdose enables new trial designs for preliminary, exploratory pharmacogenetic studies using matched groups of patients or even healthy volunteers with a predefi ned genotype of the desired signature. Th e implementation of such proof-ofprinciple approaches may not only unequivocally establish genotype-phenotype associations -or the lack thereofin a statistically sound and unbiased fashion, but the information could also be obtained faster and could save a lot of resources. Because lack of effi cacy and/or inadequate safety of investigational agents are currently the primary reasons for attrition (11), with poor pharmacokinetic properties representing only less than 10% of total attrition, microdose studies may have a limited impact on the overall effi ciency of new drug development (12). However, microdosing should become an integrated approach to human studies aimed at understanding basic pharmacokinetic properties of (approved) oncology drugs that require continuous dosing, and it is anticipated that in the near future microdosing will make a signifi cant contribution to determine the relative role of genetic variation and environmental factors in the absorption and disposition of a wide variety of agents.
No takes yet. Share an insight, caveat, or question.
Alex Sparreboom (2008) studied this question.
Synapse has enriched 9 related papers. Consider them for comparative context: